科大國創(300520.SZ):公司輔助駕駛產品FCS100產品已在創維汽車和安凱汽車實現部分量產交付
格隆匯4月23日丨科大國創(300520.SZ)4月23日在投資者互動平台表示,公司輔助駕駛產品FCS100產品已在創維汽車和安凱汽車實現部分量產交付;同時,公司主建的安徽省域控制器產業創新中心已獲批“安徽省產業創新中心”。公司後續將在現有ADAS產品的基礎上,結合安徽省域控制器產業創新中心建設,重點開展動力域控制器、自動駕駛域控制器及車身域控制器等智能汽車電子產品的研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.